-
Product Insights
New![]()
Net Present Value Model: UniQure NV’s AMT-130
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AMT-116 in Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AMT-116 in Colorectal Cancer Drug Details: AMT-116 is under development for the treatment of non-small...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AMT-116 in Cervical Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AMT-116 in Cervical Cancer Drug Details: AMT-116 is under development for the treatment of non-small...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AMT-116 in Liver Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AMT-116 in Liver Cancer Drug Details: AMT-116 is under development for the treatment of non-small...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AMT-116 in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AMT-116 in Pancreatic Cancer Drug Details: AMT-116 is under development for the treatment of non-small...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AMT-116 in Gastric Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AMT-116 in Gastric Cancer Drug Details: AMT-116 is under development for the treatment of non-small...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AMT-116 in Bladder Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AMT-116 in Bladder Cancer Drug Details: AMT-116 is under development for the treatment of non-small...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AMT-116 in Esophageal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AMT-116 in Esophageal Cancer Drug Details: AMT-116 is under development for the treatment of non-small...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AMT-116 in Biliary Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AMT-116 in Biliary Tumor Drug Details: AMT-116 is under development for the treatment of non-small...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AMT-116 in Head And Neck Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AMT-116 in Head And Neck Cancer Drug Details: AMT-116 is under development for the treatment...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.